New phase 4 data from Vertex Pharmaceuticals revealed that more than 90% of patients recovering from aesthetic or reconstructive surgery remained opioid-free when treated with Journavx (suzetrigine) ...
As the demand for proactive lifestyle management continues to gain national momentum, Boston Vitality, a premier wellness ...
Vertex Pharmaceuticals (VRTX) announced data from a Phase 4 study of JOURNAVX, a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that ...
As cyber risks and operational demands increase, local organizations seek stable, scalable IT support to protect ...
While North Sea oil and gas production continues to decline, investment in renewable energy, grid infrastructure and energy storage is rising. By 2026, annual investment in clean energy generation, ...
In the UAE’s independent wealth management sector, artificial intelligence (AI) has moved decisively beyond experimentation. The debate in 2026 is no longer about whether firms should adopt AI, but ...
NJ municipalities had to dig into emergency funds to pay for cleanup of one of the snowiest winters in recent years.
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), ...
Regenxbio (RGNX) hit by FDA CRL for RGX-121; valuation discount, cash runway to 2027, risks vs RGX-202 upside. Click here to ...
Crawford & Company has released a new report outlining how it expects the US claims market to evolve through 2026, against a backdrop of elevated catastrophe losses, rapid digitization and persistent ...
Adjusted Gross Margin -- 33.6%, up 140 basis points, reflecting favorable product mix and higher volume, slightly offset by unfavorable pricing. Adjusted Operating Margin -- Improved by 230 basis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results